- Home
- ZOM vs RDIB Comparison
ZOM vs RDIB Comparison
Compare ZOM & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZOM
- RDIB
- Stock Information
- Founded
- ZOM 2015
- RDIB 1937
- Country
- ZOM United States
- RDIB United States
- Employees
- ZOM N/A
- RDIB N/A
- Industry
- ZOM Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- ZOM Health Care
- RDIB Consumer Discretionary
- Exchange
- ZOM Nasdaq
- RDIB Nasdaq
- Market Cap
- ZOM 135.9M
- RDIB 162.8M
- IPO Year
- ZOM N/A
- RDIB N/A
- Fundamental
- Price
- ZOM $0.13
- RDIB $6.41
- Analyst Decision
- ZOM
- RDIB
- Analyst Count
- ZOM 0
- RDIB 0
- Target Price
- ZOM N/A
- RDIB N/A
- AVG Volume (30 Days)
- ZOM 7.3M
- RDIB 4.2K
- Earning Date
- ZOM 11-07-2024
- RDIB 12-03-2024
- Dividend Yield
- ZOM N/A
- RDIB N/A
- EPS Growth
- ZOM N/A
- RDIB N/A
- EPS
- ZOM N/A
- RDIB N/A
- Revenue
- ZOM $26,727,000.00
- RDIB $197,270,000.00
- Revenue This Year
- ZOM $36.75
- RDIB N/A
- Revenue Next Year
- ZOM $14.92
- RDIB $13.64
- P/E Ratio
- ZOM N/A
- RDIB N/A
- Revenue Growth
- ZOM 11.33
- RDIB N/A
- 52 Week Low
- ZOM $0.12
- RDIB $5.96
- 52 Week High
- ZOM $0.23
- RDIB $21.34
- Technical
- Relative Strength Index (RSI)
- ZOM 51.79
- RDIB 41.29
- Support Level
- ZOM $0.12
- RDIB $5.96
- Resistance Level
- ZOM $0.16
- RDIB $7.00
- Average True Range (ATR)
- ZOM 0.01
- RDIB 0.43
- MACD
- ZOM 0.00
- RDIB -0.01
- Stochastic Oscillator
- ZOM 33.95
- RDIB 20.79
About ZOM Zomedica Corp.
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.